Health
Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer – FierceBiotech
Georgetown researchers reported that combining BioXcel’s DPP inhibitor talabostat with a PD-1 blocker in mouse models of pancreatic…
When BioXcel Therapeutics raised $60 million in an initial public offering a few years back, it said it would pour part of the proceeds into developing talabostat, a drug that failed a phase 3 trial in pancreatic cancer in 2007. Now, BioXcel, along with…
Continue Reading
-
General13 hours agoHungarian British author David Szalay wins Booker Prize 2025 for his novel Flesh
-
Business16 hours agoWhere to invest $5,000 in ASX ETFs in November
-
General15 hours agoOwners barred from Beachport holiday units after council fire safety change
-
Business17 hours agoIf a 40-year-old invests $1,000 a month in ASX stocks, here’s how much they could have by retirement